CRISPR Therapeutics AG (CRSP) Equity Income (2016 - 2019)

CRISPR Therapeutics AG has disclosed Equity Income across 4 years of filings, most recently posting -$3.4 million for Q3 2019.

• In Q3 2019, Equity Income fell 238.93% year-over-year to -$3.4 million; the TTM figure through Dec 2019 stood at -$5.5 million (down 27.88% YoY), while the FY2019 annual figure was -$5.5 million, down 27.88% from the prior year.
• Equity Income came in at -$3.4 million for Q3 2019 at CRISPR Therapeutics AG, down from -$1.0 million in the prior quarter.
• In the past five years, Equity Income ranged from a high of -$359000.0 in Q3 2017 to a low of -$35.8 million in Q4 2016.
• Average Equity Income over 4 years is -$3.7 million, with a median of -$1.0 million recorded in 2018.
• Year-over-year, Equity Income soared 98.74% in 2017 and sank 238.93% in 2019.
• Over 4 years, Equity Income stood at -$35.8 million in 2016, then soared by 98.74% to -$453000.0 in 2017, then slumped by 124.94% to -$1.0 million in 2018, then sank by 236.6% to -$3.4 million in 2019.
• Per Business Quant data, the three most recent Equity Income figures were -$3.4 million in Q3 2019, -$1.0 million in Q2 2019, and -$1.0 million in Q1 2019.